Exploring humanistic burden of fatigue in adults with multiple sclerosis: an analysis of US National Health and Wellness Survey data

Table 2 MS prescription use, treatment satisfaction, and reasons for switching medications

	RRMS+LF (MFIS-5=0-14)		RRMS+HF (MFIS-5=15+)		p Value
	(N=375)		(N=123)
	Mean/n	SD/%	Mean/n	SD/%
MS Prescription Use (% yes)
Current Use	278	74.13	88	71.54	0.655
Prior Use	157	98.12	47	94.00	0.297
Overall Treatment Satisfaction^a	5.73	1.20	4.89	1.58	<0.001
Reasons for Switching MS Medication (% yes)
Physician Recommendation	89	56.69	18	38.30	0.041
Side Effects	43	27.39	22	46.81	0.020
Lower Cost	4	2.55	2	4.26	0.908
Not Effective	48	30.57	15	31.91	>0.999
Dosing	24	15.29	7	14.89	>0.999
Mode of Administration	39	24.84	12	25.53	>0.999
Other	12	7.64	3	6.38	>0.999

For the set of tests shown in the table, the corrected alpha level was 0.005 for comparisons between RRMS+LF and RRMS+HF. The differences between RRMS+LF and RRMS+HF in reporting side effects (p=0.020 > p=0.005) and physician recommendation (p=0.041 > p=0.005) as reasons for switching MS medication were no longer statistically significant
HF high fatigue, LF low fatigue, MFIS-5 5-item Modified Fatigue Impact Scale, MS multiple sclerosis, RRMS relapsing-remitting multiple sclerosis, SD standard deviation
^aOn a 7-point Likert scale in which 1 = extremely dissatisfied and 7 = extremely satisfied

ISSN: 1471-2377